These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 16795150)

  • 21. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Influenza A/H5N1 virus outbreaks and prepardness to avert flu pandemic].
    Haque A; Lucas B; Hober D
    Ann Biol Clin (Paris); 2007; 65(2):125-33. PubMed ID: 17353166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine.
    Lin JT; Li CG; Wang X; Su N; Liu Y; Qiu YZ; Yang M; Chen JT; Fang HH; Dong XP; Yin WD; Feng ZJ
    J Infect Dis; 2009 Jan; 199(2):184-7. PubMed ID: 19067606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of inactivated influenza vaccine in children.
    Wright PF
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):200-5. PubMed ID: 17055371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
    Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influenza vaccine 2005-2006.
    Med Lett Drugs Ther; 2005 Oct; 47(1220):85-7. PubMed ID: 16264371
    [No Abstract]   [Full Text] [Related]  

  • 28. [H5N1: vaccine solutions for humans and other animals].
    Durand MP
    Bull Acad Natl Med; 2006; 190(4-5):963-72. PubMed ID: 17195620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunology. Flu antibodies stir new hope for treatment, vaccine.
    Leslie M
    Science; 2009 Feb; 323(5918):1160. PubMed ID: 19251602
    [No Abstract]   [Full Text] [Related]  

  • 30. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
    Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
    J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Research of real-time fluorescent PCR in the rapid differential detection of H5, H9, H7 subtype avian influenza inactivated vaccines].
    Han JF; Ning YB; Song L; Yang CH
    Sheng Wu Gong Cheng Xue Bao; 2007 Sep; 23(5):953-7. PubMed ID: 18051881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations].
    de Jong JC; Osterhaus AD
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2113-5. PubMed ID: 18856026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.
    Lu X; Edwards LE; Desheva JA; Nguyen DC; Rekstin A; Stephenson I; Szretter K; Cox NJ; Rudenko LG; Klimov A; Katz JM
    Vaccine; 2006 Nov; 24(44-46):6588-93. PubMed ID: 17030078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intanza(®): a new intradermal vaccine for seasonal influenza.
    Atmar RL; Patel SM; Keitel WA
    Expert Rev Vaccines; 2010 Dec; 9(12):1399-409. PubMed ID: 21105776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H5N1 influenza marker vaccine for serological differentiation between vaccinated and infected chickens.
    Li C; Ping J; Jing B; Deng G; Jiang Y; Li Y; Tian G; Yu K; Bu Z; Chen H
    Biochem Biophys Res Commun; 2008 Jul; 372(2):293-7. PubMed ID: 18501701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
    J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia.
    Isoda N; Sakoda Y; Kishida N; Soda K; Sakabe S; Sakamoto R; Imamura T; Sakaguchi M; Sasaki T; Kokumai N; Ohgitani T; Saijo K; Sawata A; Hagiwara J; Lin Z; Kida H
    Arch Virol; 2008; 153(9):1685-92. PubMed ID: 18651092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.